Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_assertion type Assertion NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_head.
- NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_assertion wasGeneratedBy ECO_0000203 NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_provenance.
- NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_assertion wasDerivedFrom befree-20150227 NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_provenance.
- NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_assertion SIO_000772 20616366 NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_provenance.
- NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_assertion evidence source_evidence_literature NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_provenance.
- NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_assertion description "[KRAS mutations occur in 30-50% of colorectal cancers (CRCs) and represent a marker of clinical resistance to cetuximab therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP527899.RAxoXTsjf34_-JczIBhEI3pAA1mTjNRdyuOSjd_bKNZDc130_provenance.